Eisai
Lion TCR to Begin Phase Ib/II Trial of Autologous Liver Cancer T-Cell Receptor Therapy
The FDA has cleared an investigational new drug application for Lion's LioCyx-M004 for advanced hepatitis B virus-related hepatocellular carcinoma patients.
FDA Grants Full Approval to Merck, Eisai's Keytruda, Lenvima Combo in Endometrial Cancer
Based on results from the Phase III Keynote-775 trial, the agency converted its prior accelerated approval of the regimen to full approval.
Bristol Myers Squibb Licenses Eisai's Anti-Folate Receptor Alpha Antibody for up to $3.1B
The companies will jointly develop and commercialize Eisai's MORAb-202, which is being studied in folate receptor alpha-positive solid tumors.
Merck, Eisai to Discuss Positive Keytruda, Lenvima Data in Endometrial Cancer With Regulators
The Phase III Keynote-775 study has shown that the combination improves overall and progression-free survival compared to chemotherapy.
Bristol-Myers Squibb, H3 Biomedicine Form Cancer Immunotherapy Alliance
H3, a subsidiary of Japanese drugmaker Eisai, is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing.